Singapore, Nov. 19 -- South Korea-based ABL Bio, a company specializing in bispecific antibodies, has entered license, research and collaboration agreement with American pharma major Eli Lilly and Company for the development of therapeutics by utilising ABL Bio's Grabody Platform.

ABL Bio and Lilly will collaborate to develop multiple therapeutics across modalities & therapeutic areas utilising the Grabody Platform.

Under the terms of the agreement, ABL Bio will receive an upfront payment of $40 million within 10 days following the completion of the administrative procedures under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). In addition to the upfront payment, ABL Bio is eligible to receive up to $2.562 billion in develop...